VKTX · Company research

Viking Therapeutics, Inc.

2 upcoming catalysts · 0 phase 2+ trials on file

View Stock opens Yahoo Finance. Prices and performance charts are provided there.

Upcoming catalysts

MilestoneVKTXVikingQ4 2026

Initiation of Phase 3 program for oral VK2735, expected in Q4 2026 (Oct–Dec) (no exact date yet). A company milestone for Viking (VK2735 (oral) for Obesity): a step in the program rather than a decision or a data readout.

More details

Entry

Initiation of Phase 3 program for oral VK2735 · Company milestone

Drug

VK2735 (oral)

For

Obesity

Stage

Phase 3 · the last stage before a drug can be approved

When

Q4 2026 · the company gave a window, not a day

Source note

Q2 2026 PR: oral VK2735 Phase 3 'expected to begin in the fourth quarter of this year' following positive 13-week Phase 2 VENTURE-Oral data.

Checked

Checked by a person when it was added

Verify it

Source: prnewswire.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
VKTX headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsVKTXViking2027

Viking expects to report results from its Phase 3 study of VK2735 (subcutaneous) for Obesity (VANQUISH-1, n~4,650) and obesity/overweight with T2D (VANQUISH-2, n~1,000) during 2027 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.

More details

Entry

VANQUISH-1 and VANQUISH-2 Phase 3 topline (subcutaneous VK2735 in obesity/T2D) · Clinical trial results (readout / topline data)

Drug

VK2735 (subcutaneous)

For

Obesity (VANQUISH-1, n~4,650) and obesity/overweight with T2D (VANQUISH-2, n~1,000)

Stage

Phase 3 · the last stage before a drug can be approved

When

2027 · the company gave a window, not a day

Source note

Both 78-week trials are fully enrolled (VANQUISH-1 Nov 2025, VANQUISH-2 Mar 2026) and 'proceeding according to plan'; coverage of company guidance points to completion/data in 2027 (some coverage says late 2027). Company has not press-released a specific topline quarter, hence year precision and MEDIUM.

Checked

Checked by a person when it was added

Verify it

Source: finance.yahoo.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
VKTX headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Past catalysts

Trial resultsVKTXVikingQ3 2026

Viking reported results from its Phase 2 study of VK2735 (subcutaneous) for Obesity (weight maintenance) in Q3 2026 (Jul–Sep). The linked source has what the numbers showed.

More details

Entry

VK2735 subcutaneous maintenance dosing study results · Clinical trial results (readout / topline data)

Drug

VK2735 (subcutaneous)

For

Obesity (weight maintenance)

Stage

Phase 2 · the stage that tests whether the drug actually works

When

Q3 2026 · the company gave a window, not a day

Source note

Q2 2026 PR (July 29, 2026): 'The company expects to report the results of the study in 3Q26.'

Checked

Checked by a person when it was added

Verify it

Source: prnewswire.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
VKTX headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

MilestoneVKTXVikingJun 24, 2026

Viking starts Phase 1 study of amylin agonist VK3019 in obesity, on Jun 24, 2026. A company milestone for Viking (VK3019 for Obesity): a step in the program rather than a decision or a data readout.

More details

Entry

Viking starts Phase 1 study of amylin agonist VK3019 in obesity · Company milestone

Drug

VK3019

For

Obesity

Stage

Phase 1 · an early safety study in a small group of people

When

Jun 24, 2026

Source note

Viking dosed the first cohort in a randomized, placebo-controlled single-ascending-dose study of VK3019, a dual amylin and calcitonin receptor agonist, following FDA clearance of the IND. It broadens Viking's obesity portfolio beyond VK2735.

Checked

Checked by a person when it was added

Verify it

Source: ir.vikingtherapeutics.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
VKTX headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

ConferenceVKTXVikingMay 12, 2026

Viking presented data on VK2735 (oral tablet) for Obesity at a medical meeting on May 12, 2026. The linked source has the details.

More details

Entry

Oral VK2735 Phase 2 data at ECO 2026: up to 12.2% weight loss at 13 weeks · Data presented at a medical meeting

Drug

VK2735 (oral tablet)

For

Obesity

Stage

Phase 2 · the stage that tests whether the drug actually works

When

May 12, 2026

Source note

Viking presented the 13-week VENTURE-Oral Dosing dataset at the European Congress on Obesity, showing dose-dependent mean weight loss up to 12.2% with no plateau. Baseline characteristics from the ongoing Phase 3 VANQUISH-1 study were shown in a second poster.

Checked

Checked by a person when it was added

Verify it

Source: prnewswire.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
VKTX headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

MilestoneVKTXVikingMar 26, 2026

Phase 3 VANQUISH-2 of VK2735 completes enrollment (~1,000 patients), on Mar 26, 2026. A company milestone for Viking (VK2735 (subcutaneous) for Obesity with type 2 diabetes): a step in the program rather than a decision or a data readout.

More details

Entry

Phase 3 VANQUISH-2 of VK2735 completes enrollment (~1,000 patients) · Company milestone

Drug

VK2735 (subcutaneous)

For

Obesity with type 2 diabetes

Stage

Phase 3 · the last stage before a drug can be approved

When

Mar 26, 2026

Source note

Viking said it finished enrolling roughly 1,000 adults with type 2 diabetes and obesity/overweight into the 78-week VANQUISH-2 trial of once-weekly subcutaneous VK2735. Both pivotal VANQUISH studies are now fully enrolled.

Checked

Checked by a person when it was added

Verify it

Source: ir.vikingtherapeutics.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
VKTX headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsVKTXVikingFeb 27, 2024

Viking reported results from its Phase 2 study of VK2735 for Obesity on Feb 27, 2024. The linked source has what the numbers showed.

More details

Entry

VENTURE Phase 2 topline: up to 14.7% weight loss at 13 weeks · Clinical trial results (readout / topline data)

Drug

VK2735

For

Obesity

Stage

Phase 2 · the stage that tests whether the drug actually works

When

Feb 27, 2024

Source note

VK2735 dual GLP-1/GIP agonist beat expectations in obesity.

Checked

Checked by a person when it was added

Verify it

SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
VKTX headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Things of Interest

Explore reported politician transactions and public investor statements connected to VKTX.

View source-linked activity ↗

Pipeline trials

ClinicalTrials.gov · phase 2 and later

No phase 2+ trials cached for this company.

Company news

No recent headlines on file.